167 related articles for article (PubMed ID: 15325801)
1. Committed memory effector type 2 cytotoxic T (Tc2) cells are ineffective in protective anti-tumor immunity.
Do JS; Choi YH; Shin SH; Yi HK; Hwang PH; Nam SY
Immunol Lett; 2004 Aug; 95(1):77-84. PubMed ID: 15325801
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
[TBL] [Abstract][Full Text] [Related]
3. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
4. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions.
Li L; Sad S; Kägi D; Mosmann TR
J Immunol; 1997 May; 158(9):4152-61. PubMed ID: 9126975
[TBL] [Abstract][Full Text] [Related]
5. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.
Cerwenka A; Carter LL; Reome JB; Swain SL; Dutton RW
J Immunol; 1998 Jul; 161(1):97-105. PubMed ID: 9647212
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
[TBL] [Abstract][Full Text] [Related]
7. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
Vinay DS; Kwon BS
Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity.
Sad S; Krishnan L; Bleackley RC; Kägi D; Hengartner H; Mosmann TR
Eur J Immunol; 1997 Apr; 27(4):914-22. PubMed ID: 9130644
[TBL] [Abstract][Full Text] [Related]
9. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
[TBL] [Abstract][Full Text] [Related]
10. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abdulsamad K; Adams SL
Immunol Invest; 2008; 37(4):315-38. PubMed ID: 18569073
[TBL] [Abstract][Full Text] [Related]
11. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
Liu Y; Bi X; Xu S; Xiang J
Cancer Res; 2005 Jun; 65(11):4955-62. PubMed ID: 15930318
[TBL] [Abstract][Full Text] [Related]
13. A tumor-specific Th2 clone initiating tumor rejection via primed CD8+ cytotoxic T-lymphocyte activation in mice.
Shen Y; Fujimoto S
Cancer Res; 1996 Nov; 56(21):5005-11. PubMed ID: 8895757
[TBL] [Abstract][Full Text] [Related]
14. Cytokine-deficient CD8+ Tc1 cells induced by IL-4: retained inflammation and perforin and Fas cytotoxicity but compromised long term killing of tumor cells.
Sad S; Li L; Mosmann TR
J Immunol; 1997 Jul; 159(2):606-13. PubMed ID: 9218575
[TBL] [Abstract][Full Text] [Related]
15. Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma.
Touitou V; Daussy C; Bodaghi B; Camelo S; de Kozak Y; Lehoang P; Naud MC; Varin A; Thillaye-Goldenberg B; Merle-Béral H; Fridman WH; Sautès-Fridman C; Fisson S
Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):3223-9. PubMed ID: 17591892
[TBL] [Abstract][Full Text] [Related]
16. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
17. Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity.
Lin YC; Chang LY; Huang CT; Peng HM; Dutta A; Chen TC; Yeh CT; Lin CY
J Immunol; 2009 May; 182(10):6095-104. PubMed ID: 19414761
[TBL] [Abstract][Full Text] [Related]
18. Functions of CD8 T-cell subsets secreting different cytokine patterns.
Mosmann TR; Li L; Sad S
Semin Immunol; 1997 Apr; 9(2):87-92. PubMed ID: 9194219
[TBL] [Abstract][Full Text] [Related]
19. Cytokine requirements for production of a novel anti-CD8-resistant CTL population.
Lamousé-Smith ES; Dougall DS; McCarthy SA
J Immunol; 1999 Oct; 163(8):4160-7. PubMed ID: 10510351
[TBL] [Abstract][Full Text] [Related]
20. IL-17/IFN-γ double producing CD8+ T (Tc17/IFN-γ) cells: a novel cytotoxic T-cell subset converted from Tc17 cells by IL-12.
Tajima M; Wakita D; Satoh T; Kitamura H; Nishimura T
Int Immunol; 2011 Dec; 23(12):751-9. PubMed ID: 22039016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
